PHASQ
Price:
$0.000001
Market Cap:
$0
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd...[Read more]
Industry
Biotechnology
IPO Date
2018-10-18
Stock Exchange
PNK
Ticker
PHASQ
According to PhaseBio Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is 0.22%. This represents a change of -115.68% compared to the average of -1.41% of the last 4 quarters.
The mean historical ROE of PhaseBio Pharmaceuticals, Inc. over the last ten years is 50.01%. The current 0.22% ROE has changed -99.56% with respect to the historical average. Over the past ten years (40 quarters), PHASQ's ROE was at its highest in in the June 2021 quarter at 149.56%. The ROE was at its lowest in in the September 2020 quarter at -577.73%.
Average
50.01%
Median
5.33%
Minimum
-65.44%
Maximum
391.10%
Discovering the peaks and valleys of PhaseBio Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 39.75%
Maximum Annual ROE = 391.10%
Minimum Annual Increase = -697.69%
Minimum Annual ROE = -65.44%
Year | ROE | Change |
---|---|---|
2021 | 0.14% | -99.96% |
2020 | 391.10% | -697.69% |
2019 | -65.44% | 39.75% |
2018 | -46.82% | -545.14% |
2017 | 10.52% | -0.54% |
The current ROE of PhaseBio Pharmaceuticals, Inc. (PHASQ) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
108.60%
5-year avg
57.90%
10-year avg
50.01%
PhaseBio Pharmaceuticals, Inc.’s ROE is greater than Ceapro Inc. (-21.67%), greater than Oncotelic Therapeutics, Inc. (-41.44%), greater than Processa Pharmaceuticals, Inc. (-195.22%), greater than Kaleido Biosciences, Inc. (0%),
Company | ROE | Market cap |
---|---|---|
-21.67% | $13.31M | |
-41.44% | $12.63M | |
-195.22% | $2.81M | |
0% | $4.26K |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like PhaseBio Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like PhaseBio Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is PhaseBio Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for PhaseBio Pharmaceuticals, Inc. (PHASQ)?
What is the highest ROE for PhaseBio Pharmaceuticals, Inc. (PHASQ)?
What is the 3-year average ROE for PhaseBio Pharmaceuticals, Inc. (PHASQ)?
What is the 5-year average ROE for PhaseBio Pharmaceuticals, Inc. (PHASQ)?
How does the current ROE for PhaseBio Pharmaceuticals, Inc. (PHASQ) compare to its historical average?